loading...| Preferred Name |
Ticlopidine Hydrochloride |
|
| Synonyms |
|
|
| Definitions |
The hydrochloride salt form of ticlopidine, a thienopyridine derivative with anticoagulant property. Ticlopidine hydrochloride irreversibly inhibits adenosine-diphosphate (ADP)-induced platelet-fibrinogen binding by binding to the glycoprotein (GP) IIb/IIIA complex, one of the two purinergic receptors activated by ADP. Inhibition of the receptor activation causes the inhibition of adenylyl cyclase, results in decreased levels of cyclic adenosine monophosphate and thereby interferes with platelet membrane function and subsequent, platelet-platelet interaction, release of platelet granule constituents and prolongation of bleeding time. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C47756 |
|
| CAS_Registry |
53885-35-1 |
|
| CHEBI_ID |
CHEBI:9589 |
|
| Chemical_Formula |
C14H14ClNS.HCl |
|
| code |
C47756 |
|
| Contributing_Source |
FDA |
|
| definition |
The hydrochloride salt form of ticlopidine, a thienopyridine derivative with anticoagulant property. Ticlopidine hydrochloride irreversibly inhibits adenosine-diphosphate (ADP)-induced platelet-fibrinogen binding by binding to the glycoprotein (GP) IIb/IIIA complex, one of the two purinergic receptors activated by ADP. Inhibition of the receptor activation causes the inhibition of adenylyl cyclase, results in decreased levels of cyclic adenosine monophosphate and thereby interferes with platelet membrane function and subsequent, platelet-platelet interaction, release of platelet granule constituents and prolongation of bleeding time. |
|
| FDA_UNII_Code |
A1L4914FMF |
|
| Has_Free_Acid_Or_Base_Form | ||
| in_subset | ||
| label |
Ticlopidine Hydrochloride |
|
| Legacy Concept Name |
Ticlopidine_Hydrochloride |
|
| Preferred_Name |
Ticlopidine Hydrochloride |
|
| prefixIRI |
NCIT:C47756 |
|
| prefLabel |
Ticlopidine Hydrochloride |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0000598 |
|
| subClassOf |